SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYTO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BlueCrab who wrote (7582)9/28/1999 1:30:00 PM
From: Jim Oravetz  Read Replies (2) of 8116
 
Cytogen To Acquire License To Develop Antigen Tests
PRINCETON, N.J. -- Cytogen Corp. (CYTO) signed a letter of intent to acquire the exclusive license for Molecular Staging Inc.'s Rolling Circle Amplification Technology.
Financial terms weren't disclosed.
In a press release Tuesday, Cytogen said it will use the technology to develop in-vitro diagnostic tests for prostate specific membrane antigen and prostate specific antigen.
The biopharmaceutical company said it should have an assay for clinical study by mid-2000.
Locating the antigens helps physicians identify prostate cancer, said Cytogen

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News